<DOC>
	<DOC>NCT01785329</DOC>
	<brief_summary>Primary Objective: To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553 (REGN727) administered at 3 different injection sites in healthy subjects. Secondary Objectives: - To assess the pharmacodynamic effect of a single subcutaneous dose of alirocumab SAR236553 (REGN727) on serum low-density lipoprotein cholesterol and other lipids and apolipoproteins. - To assess the safety of a single subcutaneous dose of alirocumab SAR236553 (REGN727). - To assess the immunogenicity of a single subcutaneous dose of alirocumab SAR236553 (REGN727).</brief_summary>
	<brief_title>Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects</brief_title>
	<detailed_description>Total duration of the study per subject is about 15 weeks.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Healthy subjects. Exclusion criteria: Healthy subjects with history or presence of clinically relevant illness. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>